In Vitro and In Vivo Antitumor Efficacy of Curcumol Nanosuspension against H22 Tumor

Abstract:

Hepatocarcinoma, a malignant cancer, threaten human life badly. It is a current issue to seek the effective natural remedy from plant to treat cancer due to the resistence of the advanced hepatocarcinoma to chemotherapy. Curcumol (Cur), a novel compound extracted from rhizoma curcumae, exhibits various anticancer activities and can be treat hepatocarcinoma. However, the low solubility hinders development. We evaluate both the in vitro and in vivo antitumor activity of Cur-nanosuspension (Cur-N) relative to efficacy of bulk Cur. Cur-N with a particle size of 231.2 ± 7.2 nm and a zeta potential of −27.3 ± 0.6 mV, prepared by the high-pressure homogenization (HPH) technique. CCK-8 assay showed that Cur-N effectively inhibited the proliferation of H22 cells. In vivo studies also showed higher antitumor efficacy against H22 solid tumor bearing mice. These results suggest that the delivery of Cur-N is a promising approach for treating tumors.

• Periodical: Advanced Materials Research (Volumes 998-999)
• Pages: 151-155
• DOI: https://doi.org/10.4028/www.scientific.net/AMR.998-999.151
• Online since: July 2014
• Authors: Zhi Ping Wang*, Jun Biao Wu, Qun Zhou, Hua Fan, Yi Fei Wang, Tong Sheng Chen
• Keywords: Antitumor Activity, Curcumol, Cytotoxicity, H22 Cells, Nanosuspension, Tumor Bearing Mice

References

[1] D.M. Parkin: Lancet. Oncol Vol. 2 (2001), p.533.

[2] M.B. Thomas, & A.X. Zhu: J. Clinic. Oncol Vol. 23 (2005), p.2892.

[3] X.K. Deng, W. Yin, W.D. Li, F.Z. Yin, X.Y. Lu, & X.C. Zhang: J. Ethnopharmacol Vol. 106 (2006), p.179.

[4] X.J. Li, & H.Y. Zhang: Trends. Mol. Med Vol. 14 (2008), p.1.

[5] J.J. Lu, Y.Y. Dang, M. Huang, W.S. Xu, X.P. Chen, & Y.T. Wang: J. Ethnopharmacol Vol. 143 (2012), p.406.

[6] Y. Lou, H. Zhang, H. He, K. Peng, N. Kang, X. Wei, X. Li, L. Chen, X. Yao, & F. Qiu: Drug. Metab. Dispos Vol. 38 (2010), p. (2014).

[7] C. Deng, J. Ji, N. Li, Y. Yu, G. Duan, & X. Zhang: J. Chromatogr. A Vol. 1117 (2006), p.115.

[8] Y. Jiang, Z.S. Li, F.S. Jiang, X. Deng, C.S. Yao, & G. Nie: World. J. Gastroentero Vol. 11 (2005), p.6780.

[9] L. Xu, K. Bian, Z. Liu, J. Zhou, & G. Wang: Tumor Vol. 25 (2005), p.570.

[10] W.W. Zhang, Z.P. Wang, & T.S. Chen: Med. Oncol Vol. 28 (2011), p.307.

[11] J. Wang, X. Chen, & J.H. Zeng: Chin. J. Cell. Mol. Immunol Vol. 27 (2011), p.790.

[12] L. Gao, G.Y. Liu, J.L. Ma, X.Q. Wang, L. Zhou, X. Li, & F. Wang: Pharma. Res Vol. 30 (2013), p.307.

[13] P.K. Mittapalli, M.R. Yamasani, & A. Shashank: Curr. Nanosci Vol. 4 (2008), p.53.

[14] L. Gao, D.R. Zhang, & M.H. Chen: J. Nanopart. Res Vol. 10 (2008), p.845.

[15] C.M. Keck, & R.H. Müller: Eur. J. Pharm. Biopharm Vol. 62 (2006), p.3.

[16] J.B. Sun, J.H. Duan, S.L. Dai, J. Ren, Y.D. Zhang, J.S. Tian, & Y. Li: Cancer. Letters Vol. 258 (2007), p.109.